Redx Pharma plc Redx to present preclinical data on RXC009 at ASN
30 October 2023 - 6:00PM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
30 October 2023
REDX PHARMA PLC
("Redx" or the "Company")
Redx to Present Preclinical Data on RXC009, a selective
Discoidin Domain Receptor 1 inhibitor
RXC009, recently nominated as Redx's latest development
candidate, is a potential first-in-class treatment for chronic
kidney disease and associated fibrosis
Alderley Park, UK, 30 October 2023 Redx (AIM:REDX), the
clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease and cancer announces that it will
present preclinical data from its recently-nominated development
candidate, RXC009 at the American Society of Nephrology (ASN)
Annual Meeting (2-5 November 2023, Philadelphia, PA).
Redx nominated RXC009 as a development candidate in October
2023. RXC009 is a small molecule, orally available, highly potent
and selective DDR1 inhibitor and a potential first-in-class
treatment for chronic kidney disease (CKD).
CKD affects 8% to 16% of the population worldwide and is most
commonly attributed to diabetes and hypertension. Renal fibrosis,
characterized by tubulointerstitial fibrosis and
glomerulosclerosis, is one of the final manifestations of CKD as it
progresses and is associated with high morbidity[1].
DDRs have recently gained traction as druggable targets with the
potential to treat multiple fibrotic conditions, including kidney
fibrosis associated with CKD such as in Alport Syndrome, but to
date, no selective inhibitors of DDR1 have entered the clinic.
Dr Nicolas Guisot, Vice President, Drug Discovery at Redx, will
make an oral presentation discussing preclinical data from studies
of RXC009 in a validated animal model of CKD.
Details of the presentation are as follows:
Title: Development of Novel Selective DDR1 Inhibitors
with the Potential to Treat CKD
Day/Date: November 4, 2023
Time: 4:48 - 4:57 pm
Location: Room 103, Pennsylvania Convention Center
For further information,
please contact:
Redx Pharma Plc T: +44 (0)1625 469 918
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com
Lisa Anson, Chief Executive Officer
US Office
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated T: +44 (0)203 368 3550
Adviser)
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker) T: +44 (0)203 705 9330
Claes Spång/ Satheesh Nadarajah/
David Wilson
Panmure Gordon (UK) Limited (Joint T: +44 (0)207 886 2500
Broker)
Rupert Dearden/ Freddy Crossley/
Emma Earl
FTI Consulting T: +44 (0)203 727 1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology
company focused on the discovery and development of novel, small
molecule, targeted therapeutics for the treatment of fibrotic
disease, cancer and the emerging area of cancer-associated
fibrosis, aiming initially to progress them to clinical proof of
concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product
candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in
development for interstitial lung disease and is undergoing a Phase
2a trial for idiopathic pulmonary fibrosis (IPF) with topline data
expected in H1 2024. The Company's second fibrosis candidate,
RXC008, a GI-targeted ROCK inhibitor for the treatment of
fibrostenotic Crohn's disease, is progressing towards a CTA
application during the fourth quarter of 2023. Redx's lead oncology
product candidate, the Porcupine inhibitor RXC004, being developed
as a targeted treatment for Wnt-ligand dependent cancers, is
expected to report anti-PD-1 combination Phase 2 data during the
first half of 2024, following which Redx will seek a partner for
ongoing development. In October 2023, Redx nominated its next
development candidate, RXC009 a highly potent and selective DDR1
inhibitor for the treatment of chronic kidney disease and
associated fibrosis.
The Company has a strong track record of discovering new drug
candidates through its core strengths in medicinal chemistry and
translational science, enabling the Company to discover and develop
differentiated therapeutics against biologically or clinically
validated targets. The Company's accomplishments are evidenced not
only by its wholly-owned clinical-stage product candidates and
discovery pipeline, but also by its strategic transactions,
including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA
for adult patients with mantle cell lymphoma previously treated
with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine
inhibitor targeting fibrotic diseases including IPF, which
AstraZeneca is progressing in a Phase 1 clinical study. In
addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which
Jazz is now progressing through Phase 1 clinical studies, and an
early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/ .
[1] Taken in part from Chen TK et al; JAMA. 2019 Oct 1; 322(13):
1294Ð1304.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFEDISLAFIV
(END) Dow Jones Newswires
October 30, 2023 03:00 ET (07:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Dec 2023 to Dec 2024
